{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Head%2C+Neck+Neoplasms&page=2", "query": { "condition": "Head, Neck Neoplasms", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Head%2C+Neck+Neoplasms&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-22T18:19:59.424Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03162224", "title": "Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Head and Neck Cancer", "Human Papilloma Virus" ], "interventions": [ { "name": "MEDI0457", "type": "DRUG" }, { "name": "CELLECTRA®5P device", "type": "DEVICE" }, { "name": "Durvalumab", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 35, "start_date": "2017-06-26", "completion_date": "2021-03-19", "has_results": true, "last_update_posted_date": "2022-08-25", "last_synced_at": "2026-07-22T18:19:59.424Z", "location_count": 14, "location_summary": "San Francisco, California • Orlando, Florida • Atlanta, Georgia + 10 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03162224" }, { "nct_id": "NCT00005088", "title": "Radiation Therapy and Cisplatin in Treating Patients With Advanced Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "cisplatin", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Radiation Therapy Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "0 Years to 120 Years" }, "enrollment_count": null, "start_date": "2000-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2020-10-22", "last_synced_at": "2026-07-22T18:19:59.424Z", "location_count": 239, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 182 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005088" }, { "nct_id": "NCT03625323", "title": "Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "NSCLC", "HNSCC" ], "interventions": [ { "name": "eftilagimod alpha", "type": "DRUG" }, { "name": "pembrolizumab (KEYTRUDA®)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Immutep S.A.S.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 187, "start_date": "2019-02-21", "completion_date": "2024-11-25", "has_results": true, "last_update_posted_date": "2026-04-22", "last_synced_at": "2026-07-22T18:19:59.424Z", "location_count": 1, "location_summary": "Huston, Texas", "locations": [ { "city": "Huston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03625323" }, { "nct_id": "NCT06056310", "title": "Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "Xevinapant", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "intensity-modulated radiation therapy (IMRT)", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2024-01-18", "completion_date": "2024-08-20", "has_results": true, "last_update_posted_date": "2025-09-29", "last_synced_at": "2026-07-22T18:19:59.424Z", "location_count": 5, "location_summary": "Miami Beach, Florida • Detroit, Michigan • The Bronx, New York + 2 more", "locations": [ { "city": "Miami Beach", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" }, { "city": "The Bronx", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Sioux Falls", "state": "South Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06056310" }, { "nct_id": "NCT00314262", "title": "Phase I/II Study of Chemoprevention With EGFR and COX-2 Inhibitor", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Precancerous Conditions" ], "interventions": [ { "name": "Erlotinib & Celecoxib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 17, "start_date": "2006-10", "completion_date": "2012-11", "has_results": true, "last_update_posted_date": "2014-10-24", "last_synced_at": "2026-07-22T18:19:59.424Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00314262" }, { "nct_id": "NCT06992427", "title": "High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma", "Stage I Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8", "Stage II Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8", "Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8", "Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8" ], "interventions": [ { "name": "Gabapentin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Chemotheraphy", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Analgesic Agent", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Survey Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 228, "start_date": "2025-06-05", "completion_date": "2031-04-15", "has_results": false, "last_update_posted_date": "2026-05-11", "last_synced_at": "2026-07-22T18:19:59.424Z", "location_count": 200, "location_summary": "Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 162 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06992427" }, { "nct_id": "NCT03151642", "title": "A PILOT STUDY OF DIFFUSION WEIGHTED MRI TO ASSESS ESOPHAGEAL TUMOR RESONSE TO NEOADJUVANT CHEMORADIATION", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Esophageal Cancer" ], "interventions": [ { "name": "Chemotherapy", "type": "RADIATION" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Surgery", "type": "PROCEDURE" }, { "name": "MRI Imaging", "type": "DEVICE" }, { "name": "Blood Draws", "type": "OTHER" } ], "intervention_types": [ "RADIATION", "PROCEDURE", "DEVICE", "OTHER" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2017-04-05", "completion_date": "2021-04-23", "has_results": false, "last_update_posted_date": "2021-04-26", "last_synced_at": "2026-07-22T18:19:59.424Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03151642" }, { "nct_id": "NCT02442661", "title": "Clinical Validation of a Predictive Model for the Presence of Cervical Lymph Node Metastasis in Papillary Thyroid Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Papillary Thyroid Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 103, "start_date": "2015-04", "completion_date": "2017-05", "has_results": false, "last_update_posted_date": "2017-06-12", "last_synced_at": "2026-07-22T18:19:59.424Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02442661" }, { "nct_id": "NCT05937269", "title": "Assessing Impact of Early Physiotherapy on Lymphatic Dysfunction in Head and Neck Cancer Survivorship", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphedema of Face", "Head and Neck Cancer" ], "interventions": [ { "name": "Near-infrared fluorescence lymphatic imaging", "type": "COMBINATION_PRODUCT" }, { "name": "advanced pneumatic compression therapy", "type": "DEVICE" } ], "intervention_types": [ "COMBINATION_PRODUCT", "DEVICE" ], "sponsor": "The University of Texas Health Science Center, Houston", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2023-10-12", "completion_date": "2026-02-28", "has_results": false, "last_update_posted_date": "2025-09-09", "last_synced_at": "2026-07-22T18:19:59.424Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05937269" }, { "nct_id": "NCT00605488", "title": "The Biodistribution and Potential Diagnostic Ability of 18F FACBC in Patients With Head and Neck, Breast, and Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer", "Head and Neck Cancer", "Prostate Cancer" ], "interventions": [ { "name": "novel PET tracer FACBC", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2006-04-25", "completion_date": "2017-04-06", "has_results": false, "last_update_posted_date": "2017-04-10", "last_synced_at": "2026-07-22T18:19:59.424Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00605488" } ] }